Impact of F-18-fluoride PET-CT on implementing early treatment of painful bone metastases with Sm-153 EDTMP (681 views) (PDF public 71 views)
Nucl Med Biol (ISSN: 0969-8051, 0883-2897, 0969-8051linking), 2013 May; 40(4): 518-523.
Export to BibTeX Export to EndNote
Paper type: Journal Article, Abstract, Conference, Randomized Controlled Trial,
Impact factor: 2.408, 5-year impact factor: 2.458
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84876730691&partnerID=40&md5=5e6a0a4c47796c0ddd3e099c73fbcd52
Keywords: 18f-Fluoride Pet Ct, Bone Scan, Early Bone Pain, Radionuclide Therapy, Sm-153 Edtmp, Bisphosphonic Acid Derivative, Contrast Medium, Etidronic Acid Tc 99m, Fluorine 18, Lexidronam Samarium Sm 153, Nonsteroid Antiinflammatory Agent, Zoledronic Acid, Diagnostic Agent, Organometallic Compound, Organophosphorus Compound, Samarium Ethylenediaminetetramethylenephosphonate, Article, Bone Metastasis, Bone Scintiscanning, Cancer Palliative Therapy, Cancer Radiotherapy, Clinical Article, Computer Assisted Emission Tomography, Controlled Study, Early Intervention, Human, Prostate Cancer, Randomized Controlled Trial, Visual Analog Scale, Bone Tumor, Multimodal Imaging, Pain Assessment, Pathology, Prostate Tumor, Bone Neoplasms, Fluorine Radioisotopes, Pain Measurement, Palliative Care, Prostatic Neoplasms, Time Factors, Bone Neoplasms Complications Secondary, Fluorides Diagnostic Use, Fluorine Radioisotopes Diagnostic Use, Organometallic Compounds Therapeutic Use, Organophosphorus Compounds Therapeutic Use, Pain Complications Radionuclide Imaging Radiotherapy, Prostatic Neoplasms Pathology,
Affiliations:
*** IBB - CNR ***
IRCCS, CROB, Rionero in Vulture, Italy
Institute of Biostructure and Bioimages, National Council of Research, Naples, Italy
Diagnostica per Immagini e Radioterapia, Università di Salerno, Salerno, Italy
References:
Not available.
Nucl Med Biol (ISSN: 0969-8051, 0883-2897, 0969-8051linking), 2013 May; 40(4): 518-523.
Export to BibTeX Export to EndNote
Paper type: Journal Article, Abstract, Conference, Randomized Controlled Trial,
Impact factor: 2.408, 5-year impact factor: 2.458
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84876730691&partnerID=40&md5=5e6a0a4c47796c0ddd3e099c73fbcd52
Keywords: 18f-Fluoride Pet Ct, Bone Scan, Early Bone Pain, Radionuclide Therapy, Sm-153 Edtmp, Bisphosphonic Acid Derivative, Contrast Medium, Etidronic Acid Tc 99m, Fluorine 18, Lexidronam Samarium Sm 153, Nonsteroid Antiinflammatory Agent, Zoledronic Acid, Diagnostic Agent, Organometallic Compound, Organophosphorus Compound, Samarium Ethylenediaminetetramethylenephosphonate, Article, Bone Metastasis, Bone Scintiscanning, Cancer Palliative Therapy, Cancer Radiotherapy, Clinical Article, Computer Assisted Emission Tomography, Controlled Study, Early Intervention, Human, Prostate Cancer, Randomized Controlled Trial, Visual Analog Scale, Bone Tumor, Multimodal Imaging, Pain Assessment, Pathology, Prostate Tumor, Bone Neoplasms, Fluorine Radioisotopes, Pain Measurement, Palliative Care, Prostatic Neoplasms, Time Factors, Bone Neoplasms Complications Secondary, Fluorides Diagnostic Use, Fluorine Radioisotopes Diagnostic Use, Organometallic Compounds Therapeutic Use, Organophosphorus Compounds Therapeutic Use, Pain Complications Radionuclide Imaging Radiotherapy, Prostatic Neoplasms Pathology,
Affiliations:
*** IBB - CNR ***
IRCCS, CROB, Rionero in Vulture, Italy
Institute of Biostructure and Bioimages, National Council of Research, Naples, Italy
Diagnostica per Immagini e Radioterapia, Università di Salerno, Salerno, Italy
References:
Not available.
Impact of F-18-fluoride PET-CT on implementing early treatment of painful bone metastases with Sm-153 EDTMP
This study evaluated the diagnostic impact of using skeletal F-18-fluoride PET/CT on patients with painful bone metastases to schedule an early palliative radionuclide treatment. Methods: The skeletal involvement from prostate cancer metastases was assessed by both Tc-99m-diphosphonate bone scan (BS) and F-18-fluoride PET/CT within four weeks in 24 patients (67.7 +/- 5.1 years) suffering from a borderline degree of bone pain for which radionuclide palliation was not shortly planned for administration. The BS and F-18-fluoride PET/CT results were compared, assessing the number and extension of the skeletal sites involved. Afterward, the patients were randomly assigned either to the study group (N = 12) receiving radionuclide therapy (Samarium-153 EDTMP) or to the control group (N = 12) not receiving radionuclide therapy. The short-term results from the radionuclide palliation group (evaluated with a visual analogue scale) were compared with the controls. Results: Overall, at BS, 7.6 +/- 1.4 sites were considered metastatic, involving at least 5 +/- 1 body regions. At F-18-fluoride PET/CT, 116 +/- 19 sites presented metastatic involvement with 12/12 body regions concerned. No differences were found in regards to either the number of metastatic sites or regions at both BS and F-18-fluoride PET/CT between the study group and controls (p = ns). At CT, 88 blastic metastases were identified, whereas 110 were mainly lytic. Most of mainly lytic lesions were not detectable at BS. The reduction in total discomfort and bone pain in the study group was significantly greater than in the controls (p < 0.0001). Conclusion: Sm-153 EDTMP therapy should be considered for patients with early bone pain from prostate cancer even if their BS only indicates a few metastases before the initiation of a severe pain syndrome. F-18-fluoride PET/CT may be helpful in deciding if the implementation of bone pain palliation using bone-seeking radionuclides at pain onset is necessary. (C) 2013 Elsevier Inc. All rights reserved.
This study evaluated the diagnostic impact of using skeletal F-18-fluoride PET/CT on patients with painful bone metastases to schedule an early palliative radionuclide treatment. Methods: The skeletal involvement from prostate cancer metastases was assessed by both Tc-99m-diphosphonate bone scan (BS) and F-18-fluoride PET/CT within four weeks in 24 patients (67.7 +/- 5.1 years) suffering from a borderline degree of bone pain for which radionuclide palliation was not shortly planned for administration. The BS and F-18-fluoride PET/CT results were compared, assessing the number and extension of the skeletal sites involved. Afterward, the patients were randomly assigned either to the study group (N = 12) receiving radionuclide therapy (Samarium-153 EDTMP) or to the control group (N = 12) not receiving radionuclide therapy. The short-term results from the radionuclide palliation group (evaluated with a visual analogue scale) were compared with the controls. Results: Overall, at BS, 7.6 +/- 1.4 sites were considered metastatic, involving at least 5 +/- 1 body regions. At F-18-fluoride PET/CT, 116 +/- 19 sites presented metastatic involvement with 12/12 body regions concerned. No differences were found in regards to either the number of metastatic sites or regions at both BS and F-18-fluoride PET/CT between the study group and controls (p = ns). At CT, 88 blastic metastases were identified, whereas 110 were mainly lytic. Most of mainly lytic lesions were not detectable at BS. The reduction in total discomfort and bone pain in the study group was significantly greater than in the controls (p < 0.0001). Conclusion: Sm-153 EDTMP therapy should be considered for patients with early bone pain from prostate cancer even if their BS only indicates a few metastases before the initiation of a severe pain syndrome. F-18-fluoride PET/CT may be helpful in deciding if the implementation of bone pain palliation using bone-seeking radionuclides at pain onset is necessary. (C) 2013 Elsevier Inc. All rights reserved.
Impact of F-18-fluoride PET-CT on implementing early treatment of painful bone metastases with Sm-153 EDTMP
No results. |
Impact of F-18-fluoride PET-CT on implementing early treatment of painful bone metastases with Sm-153 EDTMP
Other filter: ([btitle,keywords] "18f-Fluoride Pet Ct" ...
Gallicchio R, Scapicchio D, Nardelli A, Pellegrino T, Prisco M, Mainenti P, Sirignano C, Pedicini P, Storto G
* Assessment of residual radioactivity by a comprehensive wireless, wearable device in thyroid cancer patients undergoing radionuclide therapy and comparison with the results of a home device: a feasibility study (268 views) (PDF 63 views)
Ieee J Transl Eng Health Med (ISSN: 2168-2372linking), 2020 Dec 2; 9: 2700306-2700306.
Impact Factor: 2.53
View Export to BibTeX Export to EndNote
Gallicchio R, Giacomobono S, Nardelli A, Pellegrino T, Simeon V, Gattozzi D, Maddalena F, Mainenti PP, Storto G
* Palliative Treatment Of Bone Metastases With Samarium-153 Edtmp At Onset Of Pain (876 views)
J Bone Miner Metab (ISSN: 0914-8779), 2014 Jul; 32(4): 434-440.
Impact Factor: 2.46
View Export to BibTeX Export to EndNote
D'Antuono F, Nardelli A, Gallicchio R, Giacomobono S, Venetucci A, Pellegrino T, Leggiadro F, D'Errico N, Gattozzi D, Mainenti PP, Storto G
* Palliative Treatment of Bone Metastases with Sm-153 EDTMP at Pain Onset (494 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2013 Oct; 40: N/D-N/D.
Impact Factor: 5.217
View Export to BibTeX Export to EndNote
Nardelli A, Castaldi E, Ortosecco G, Speranza A, Storto G, Pace L, Salvatore M
* Enhancement of reaction conditions for the radiolabelling of DOTA-peptides with high activities of yttrium-90 (809 views)
Applied Radiation And Isotopes (ISSN: 1872-9800, 0969-8043, 0969-8043linking), 2011 Jan; 69(1): 52-55.
Impact Factor: 1.172
View Export to BibTeX Export to EndNote
Fabbricini R, Catalano L, Pace L, Del Vecchio S, Fonti R, Salvatore M, Rotoli B
* Bone scintigraphy and SPECT/CT in bisphosphonate-induced osteonecrosis of the jaw (702 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 2009 Aug; 50(8): 1385-1385.
Impact Factor: 6.424
View Export to BibTeX Export to EndNote
Storto G, Erra P, Pellegrino T, Nardelli A, Milone F, Di Giorgio E, Faggiano A, Castaldi E, Ortosecco G, Speranza A, Klain M, Colao A, Salvatore M, Pace L
* Efficacy and Toxicity of Peptide Receptor Radionuclide Therapy (PRRT) using medium-high activities of Y-90-DOTA-Octreotate (Y-90-DOTATATE) in patients with tumours expressing somatostatin receptors (SSTR) (721 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2008 Oct; 35: N/D-N/D.
Impact Factor: 4.532
View Export to BibTeX Export to EndNote
Storto G, Pellegrino T, Nardelli A, De Falco T, Castaldi E, Ortosecco G, Capasso E, Erra P, Speranza A, Klain M, Molino L, Di Nuzzo C, Pace L, Salvatore M
* Impact of PET-CT with F-18 Fluoride in Implementing Treatment of Painful Bone Metastases with Sm-153 EDTMP (506 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2008 Oct; 35: N/D-N/D.
Impact Factor: 4.532
View Export to BibTeX Export to EndNote
Catalano L, Del Vecchio S, Petruzziello F, Fonti R, Salvatore B, Martorelli C, Califano C, Caparrotti G, Segreto S, Pace L, Rotoli B
* Sestamibi and FDG-PET scans to support diagnosis of jaw osteonecrosis (940 views)
Ann Hematol (ISSN: 0939-5555, 0939-5555linking), 2007 Jun; 86(6): 415-423.
Impact Factor: 2.342
View Export to BibTeX Export to EndNote
Storto G, Klain M, Paone G, Liuzzi R, Molino L, Marinelli A, Soricelli A, Pace L, Salvatore M
* Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases (683 views)
Bone (ISSN: 8756-3282), 2006 Jul; 39(1): 35-41.
Impact Factor: 3.829
View Export to BibTeX Export to EndNote
Storto G, Speranza A, Pellegrino T, Panico M, Cella L, Nardelli A, Russo AA, Klain M, Soricelli A, Pace L, Salvatore M
* Activity Threshold Determining Cumulative Aderse-Effects In Patients Undergoing Peptide Receptor Radionuclide Therapy With Y-90 Octreotate (534 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2006; 33: 338-338.
Impact Factor: 4.041
View Export to BibTeX Export to EndNote
Rendina D, Mossetti G, Soscia E, Sirignano C, Insabato L, Viceconti R, Ignarra R, Salvatore M, Nunziata V
* Giant cell tumor and Paget's disease of bone in one family: geographic clustering (748 views)
Clinical Orthopaedics And Related Research (ISSN: 0009-921x), 2004 Apr; (421): 218-224.
Impact Factor: 1.403
View Export to BibTeX Export to EndNote
* Assessment of residual radioactivity by a comprehensive wireless, wearable device in thyroid cancer patients undergoing radionuclide therapy and comparison with the results of a home device: a feasibility study (268 views) (PDF 63 views)
Ieee J Transl Eng Health Med (ISSN: 2168-2372linking), 2020 Dec 2; 9: 2700306-2700306.
Impact Factor: 2.53
View Export to BibTeX Export to EndNote
Gallicchio R, Giacomobono S, Nardelli A, Pellegrino T, Simeon V, Gattozzi D, Maddalena F, Mainenti PP, Storto G
* Palliative Treatment Of Bone Metastases With Samarium-153 Edtmp At Onset Of Pain (876 views)
J Bone Miner Metab (ISSN: 0914-8779), 2014 Jul; 32(4): 434-440.
Impact Factor: 2.46
View Export to BibTeX Export to EndNote
D'Antuono F, Nardelli A, Gallicchio R, Giacomobono S, Venetucci A, Pellegrino T, Leggiadro F, D'Errico N, Gattozzi D, Mainenti PP, Storto G
* Palliative Treatment of Bone Metastases with Sm-153 EDTMP at Pain Onset (494 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2013 Oct; 40: N/D-N/D.
Impact Factor: 5.217
View Export to BibTeX Export to EndNote
Nardelli A, Castaldi E, Ortosecco G, Speranza A, Storto G, Pace L, Salvatore M
* Enhancement of reaction conditions for the radiolabelling of DOTA-peptides with high activities of yttrium-90 (809 views)
Applied Radiation And Isotopes (ISSN: 1872-9800, 0969-8043, 0969-8043linking), 2011 Jan; 69(1): 52-55.
Impact Factor: 1.172
View Export to BibTeX Export to EndNote
Fabbricini R, Catalano L, Pace L, Del Vecchio S, Fonti R, Salvatore M, Rotoli B
* Bone scintigraphy and SPECT/CT in bisphosphonate-induced osteonecrosis of the jaw (702 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 2009 Aug; 50(8): 1385-1385.
Impact Factor: 6.424
View Export to BibTeX Export to EndNote
Storto G, Erra P, Pellegrino T, Nardelli A, Milone F, Di Giorgio E, Faggiano A, Castaldi E, Ortosecco G, Speranza A, Klain M, Colao A, Salvatore M, Pace L
* Efficacy and Toxicity of Peptide Receptor Radionuclide Therapy (PRRT) using medium-high activities of Y-90-DOTA-Octreotate (Y-90-DOTATATE) in patients with tumours expressing somatostatin receptors (SSTR) (721 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2008 Oct; 35: N/D-N/D.
Impact Factor: 4.532
View Export to BibTeX Export to EndNote
Storto G, Pellegrino T, Nardelli A, De Falco T, Castaldi E, Ortosecco G, Capasso E, Erra P, Speranza A, Klain M, Molino L, Di Nuzzo C, Pace L, Salvatore M
* Impact of PET-CT with F-18 Fluoride in Implementing Treatment of Painful Bone Metastases with Sm-153 EDTMP (506 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2008 Oct; 35: N/D-N/D.
Impact Factor: 4.532
View Export to BibTeX Export to EndNote
Catalano L, Del Vecchio S, Petruzziello F, Fonti R, Salvatore B, Martorelli C, Califano C, Caparrotti G, Segreto S, Pace L, Rotoli B
* Sestamibi and FDG-PET scans to support diagnosis of jaw osteonecrosis (940 views)
Ann Hematol (ISSN: 0939-5555, 0939-5555linking), 2007 Jun; 86(6): 415-423.
Impact Factor: 2.342
View Export to BibTeX Export to EndNote
Storto G, Klain M, Paone G, Liuzzi R, Molino L, Marinelli A, Soricelli A, Pace L, Salvatore M
* Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases (683 views)
Bone (ISSN: 8756-3282), 2006 Jul; 39(1): 35-41.
Impact Factor: 3.829
View Export to BibTeX Export to EndNote
Storto G, Speranza A, Pellegrino T, Panico M, Cella L, Nardelli A, Russo AA, Klain M, Soricelli A, Pace L, Salvatore M
* Activity Threshold Determining Cumulative Aderse-Effects In Patients Undergoing Peptide Receptor Radionuclide Therapy With Y-90 Octreotate (534 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2006; 33: 338-338.
Impact Factor: 4.041
View Export to BibTeX Export to EndNote
Rendina D, Mossetti G, Soscia E, Sirignano C, Insabato L, Viceconti R, Ignarra R, Salvatore M, Nunziata V
* Giant cell tumor and Paget's disease of bone in one family: geographic clustering (748 views)
Clinical Orthopaedics And Related Research (ISSN: 0009-921x), 2004 Apr; (421): 218-224.
Impact Factor: 1.403
View Export to BibTeX Export to EndNote
11 Records (7 excluding Abstracts).
Total impact factor: 38.482 (20.16 excluding Abstracts).
Total 5 year impact factor: 37.759 (19.053 excluding Abstracts).
Total impact factor: 38.482 (20.16 excluding Abstracts).
Total 5 year impact factor: 37.759 (19.053 excluding Abstracts).
681 views. Last view on Thursday 24 April 2025, 11:20:02
ibb.cnr.it
